Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Long-Term Debt Repayments (2021 - 2025)

Journey Medical (DERM) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $625000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $625000.0, compared with a TTM value of $1.2 million through Sep 2025, changed N/A, and an annual FY2024 reading of $1.2 million, up 25.0% over the prior year.
  • Long-Term Debt Repayments was $625000.0 for Q1 2025 at Journey Medical, roughly flat from $625000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $10.0 million in Q3 2023 and bottomed at -$19.0 million in Q4 2023.
  • Average Long-Term Debt Repayments over 5 years is $255000.0, with a median of $1.4 million recorded in 2021.
  • Peak annual rise in Long-Term Debt Repayments hit 900.0% in 2023, while the deepest fall reached 1050.0% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $2.5 million in 2021, then decreased by 20.0% to $2.0 million in 2022, then crashed by 1050.0% to -$19.0 million in 2023, then soared by 103.29% to $625000.0 in 2024, then changed by 0.0% to $625000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for DERM at $625000.0 in Q1 2025, $625000.0 in Q4 2024, and -$19.0 million in Q4 2023.